Literature DB >> 12744895

IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis.

Carolina de Oliveira Mendes1, Edilma Paraguai de Souza, Gulnara Patrícia Borja-Cabrera, Leopoldina Maria Melo Batista, Miriam Aparecida dos Santos, Luciana Ellner Parra, Ingrid Menz, Marcos Palatnik, Clarisa Beatriz Palatnik de Sousa.   

Abstract

Canine antibody IgG, IgG1 and IgG2 anti-FML responses were investigated in dogs vaccinated with the fucose-mannose ligand (FML)-vaccine of Leishmania donovani and in dogs with naturally acquired visceral leishmaniosis. While similar levels of total IgG antibodies were seen in the seropositive naturally infected dogs and in vaccinees, significant differences between the groups were found regarding their IgG1/IgG2 anti-FML antibody composition (P<0.005). Higher IgG1 absorbencies were seen in infected dogs, while the IgG2 subtype was predominant in pre-immune sera, and in vaccinated animals, both after the first and the third dose (P<0.005). The average ratio between IgG1/IgG2 was then 1.124 for infected animals and 0.733 for FML-vaccinees. Also, a significant increase in IgG2 antibodies was observed from the first to the third vaccine injection (P<0.005). In the infected dogs, a high correlation between their IgG absorbance (Abs) values and the number of symptoms (P=0.017) was disclosed. Thus, the analysis of IgG subclasses disclosed a dichotomous response to visceral leishmaniosis: IgG1 associated to natural infection and IgG2 associated to a humoral response subsequent to the FML-vaccine treatment. An IgG1/IgG2>or=1 would characterize the sera of visceral leishmaniasis infected animals evoluting towards the overt disease while ratios <or=1 would characterize the sera response of vaccinated protected dogs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12744895     DOI: 10.1016/s0264-410x(03)00046-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  T cell hypo-responsiveness against Leishmania major in MAP kinase phosphatase (MKP) 2 deficient C57BL/6 mice does not alter the healer disease phenotype.

Authors:  Juliane Schroeder; H Adrienne McGachy; Stuart Woods; Robin Plevin; James Alexander
Journal:  PLoS Negl Trop Dis       Date:  2013-02-21

2.  Methods of Control of the Leishmania infantum Dog Reservoir: State of the Art.

Authors:  Michele Podaliri Vulpiani; Luigi Iannetti; Daniela Paganico; Filomena Iannino; Nicola Ferri
Journal:  Vet Med Int       Date:  2011-07-07

3.  Vaccination with recombinant aspartic hemoglobinase reduces parasite load and blood loss after hookworm infection in dogs.

Authors:  Alex Loukas; Jeffrey M Bethony; Susana Mendez; Ricardo T Fujiwara; Gaddam Narsa Goud; Najju Ranjit; Bin Zhan; Karen Jones; Maria Elena Bottazzi; Peter J Hotez
Journal:  PLoS Med       Date:  2005-10-04       Impact factor: 11.069

4.  Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.

Authors:  Mehdi Shahbazi; Farnaz Zahedifard; Tahereh Taheri; Yasaman Taslimi; Shahram Jamshidi; Sadegh Shirian; Niousha Mahdavi; Mehdi Hassankhani; Yahya Daneshbod; Sayyed Hamid Zarkesh-Esfahani; Barbara Papadopoulou; Sima Rafati
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

Review 5.  Biomarkers Associated With Leishmania infantum Exposure, Infection, and Disease in Dogs.

Authors:  Carla Maia; Lenea Campino
Journal:  Front Cell Infect Microbiol       Date:  2018-09-06       Impact factor: 5.293

Review 6.  Nucleoside Hydrolase NH 36: A Vital Enzyme for the Leishmania Genus in the Development of T-Cell Epitope Cross-Protective Vaccines.

Authors:  Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2019-04-16       Impact factor: 7.561

7.  Vaccines for canine leishmaniasis.

Authors:  Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2012-04-17       Impact factor: 7.561

8.  Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.

Authors:  Elodie Petitdidier; Julie Pagniez; Gérard Papierok; Philippe Vincendeau; Jean-Loup Lemesre; Rachel Bras-Gonçalves
Journal:  PLoS Negl Trop Dis       Date:  2016-05-25

9.  Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil.

Authors:  G P Borja-Cabrera; F N Santos; F S Bauer; L E Parra; I Menz; A A Morgado; I S Soares; L M M Batista; C B Palatnik-de-Sousa
Journal:  Vaccine       Date:  2008-08-22       Impact factor: 3.641

10.  Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine.

Authors:  F N Santos; G P Borja-Cabrera; L M Miyashiro; J Grechi; A B Reis; M A B Moreira; O A Martins Filho; M C R Luvizotto; I Menz; L M Pessôa; P R Gonçalves; M Palatnik; C B Palatnik-de-Sousa
Journal:  Vaccine       Date:  2007-06-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.